Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Launched by GALDERMA R&D · Feb 17, 2007

Keywords

ClinConnect Summary

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaque severity (TPS) rating between Weeks 0 and 4.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe
• • At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter
• • History of stable plaque psoriasis of greater than or equal to 3 months
• Exclusion Criteria:
• • Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis
• • Psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period
• • Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits